Precision Diagnostics And Medicine

Our nano IgG-like antibodies offer unparalleled specificity and precision, providing an ideal solution to tackle multiple sites on diverse protein targets.



We're pushing the boundaries of medical science with our cutting-edge ELISA technology tailored for both research and diagnostic purposes. Our refined methods promise unparalleled accuracy in protein quantification, setting new standards in the biotechnological field.

Specialized development of small peptides between 30 to 75 amino acids.

Combining molecular interaction dynamics with AI & high-performance computing, Designed Biologics thrives in architecting peptides that can bind and deactivate protein targets.

These AI driven peptides can be used as therapeutics and diagnostic tools, as well as for research purposes.

30-75 Residues

Rapid generation of small and penetrable peptide inhibitors.

We are able to rapidly generate candidates with programmable sizes and dynamic constraints. The short peptides we design have the added benefit of also being highly cost effective.

Targeted Precision

We have a 100% experimental success rate with a typical 50% candidate binding rate.

With over 10 successful projects including spike to G-coupled proteins, our time tested technology has been used to create peptides against a variety of targets.

Diverse Targets

We are able to generate inhibitors against even the hardest targets.

KRASb has been considered undruggable for over 30 years. We created multiple inhibitors with a success rate of ~50% in under a year.

Specificity

Our platform guarantees unparalleled specificity and precision.

Using proprietary AI, we are able to rapidly screen candidates against the entire human proteome, minimizing the possibility of undesired interactions.

Multi-target

We enable the design of multiple inhibitors against the same target.

The approach we employ has been carefully designed to even support multiple concurrent binders to the same target.

Affinity

Our biologics have been demonstrated to possess remarkable affinities towards their targets.

DesignedBiologics' mature algorithms not only produce high affinity candidates, but also outperform alternatives such as RFdiffusion.

Distinct

The sequences we design are evolutionarily distinct and unique.

Our novel approach to biologics design enables us to rapidly generate a plethora of unique and evolutionarily distinct candidates.

Multipurposed

The peptides we create can be designed for a variety of purposes.

The robustness of our proprietary pipelines allows us to create peptides for anything from therapeutics to test kits.

Nature Journal
Precision BioLogic
NIH
Health Canada
Duke University
University of Regina
BMC
NAR
Agriculture and Agri-Food Canada
iScience

Select Plans & Projects

KRASb Inhibitor

TYPE: Cancer Therapeutic
BINDING RATE: 50%
AFFINITY: nM range

HPV18 L1 Inhibitor

TYPE: Therapeutic
BINDING RATE: 50%
AFFINITY: nM range

Hemostasis Diagnostic

TYPE: Diagnostic
BINDING RATE: 66%
AFFINITY: confidential

SARS-CoV-2 S protein

TYPE: Therapeutic & Diagnostic
BINDING RATE: 50%
AFFINITY: 6nM

GP1BA-VWF

TYPE: Therapeutic
BINDING RATE: 50%
AFFINITY: 60nM

Psk1

TYPE: Therapeutic
BINDING RATE: 100%
AFFINITY: 3nM

*Binding rate refers to the number of screened candidates per batch that have been experimentally validated to interact with their target.

Select Publications

Sep 2022 | NAR Genomics Bioinformatics | Hajikarimlou et al 2022

A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein

Contact Us

Interested in collaborating or developing peptides? Fill out the form below and we'll try our best to get back to you within a few days.